TIL therapy in China is primarily available through hospital-approved clinical protocols and registered trials at major cancer centers, rather than as a broadly marketed commercial product. Availability depends on your tumor type, prior treatments, and a center's current enrollment. SinoCareBridge reviews your records and identifies centers with active, appropriately-matched TIL protocols. We only work with NMPA-registered hospitals with GMP-certified cell labs.

TIL therapy has shown the strongest evidence in melanoma, with promising results in cervical cancer and ongoing research in head and neck cancer, lung cancer, and other solid tumors. It is generally studied in patients with advanced or metastatic disease who have progressed after standard treatments. Not every tumor type or patient qualifies — eligibility depends on tumor tissue availability, prior treatments, and overall health.

CAR-T therapy uses T cells taken from your blood and genetically engineered to target a single antigen — it works best on blood cancers. TIL therapy uses immune cells taken from your tumor tissue, expanded without genetic modification, and recognizes multiple tumor antigens naturally — it is designed for solid tumors. Your physician determines which approach (if any) is appropriate for your specific cancer.

The complete cycle takes approximately 5–8 weeks: tumor collection (week 1), TIL manufacturing (3–5 weeks), lymphodepletion and infusion (week 5–6), then monitoring and recovery (2–4 weeks in-hospital). Patients typically need to be in China for 6–8 weeks. Your coordinator provides a personalized timeline after treatment planning.

Common side effects include those from lymphodepletion chemotherapy (low blood counts, infection risk) and IL-2 support (fever, chills, capillary leak symptoms). Immune-related effects from the infused T cells can also occur. Most side effects are manageable in a specialized cell therapy unit. Serious adverse events require close monitoring, which is why treatment is only done at accredited centers with experienced teams.

Yes. International patients can be evaluated for TIL clinical protocols at Chinese centers. The process includes: medical record review, tumor tissue logistics (samples may need to be shipped or collected in China), hospital acceptance, medical visa (S2 for caregiver), treatment, and follow-up. Language support and caregiver coordination are provided throughout.